Saturday afternoon Q & A (2017 Conference) (LDN, low dose naltrexone)

Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Ulcerative Colitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

SIBO - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

Atopic Dermatitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)

Atopic dermatitis is a hereditary skin disorder, and the most common form of eczema. Dr. Smith reviews the pathophysiology and diagnostic criteria for atopic dermatitis, as well as some causes.

Nuts and Bolts of The Thyroid Gland: Therapeutic Targets by Sarah Zielsdorf, MD (2021 Conference) (LDN, low dose naltrexone)

Drug Resistant Depression - Elizabeth Livengood, NMD (2021 Conference) (LDN, low dose naltrexone)

Dr. Elizabeth Livengood’s presentation is on identifying different causes of depression, identifying depression, hyperthyroidism connections, identifying patient profiles who fit these descriptions, and understanding how to treat them. 

Leonard Weinstock, MD - Inflammatory Bowel Disease I (2017 Conference) (LDN, low dose naltrexone)

Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)

Dr Sarah Zielsdorf, LDN Radio Show 2016 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Dr Sarah Zielsdorf shares her Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.